Lanreotide Depot/Autogel for Symptomatic Control of Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs) Previously Responsive to Octreotide: Subanalysis of Patient-Reported Symptoms From the Phase 3 ELECT Study Meeting Abstract

sustainable development goals

authors

publication date

  • March 1, 2018

webpage

published in

start page

  • 352

end page

  • 352

volume

  • 47

issue

  • 3